Back to today’s briefing

Story perspectives

FDA Approves Vykat XR: New Hope for Prader-Willi Syndrome

3/28/2025

25 3

Summary

Story summary

The FDA's recent approval of Vykat XR (diazoxide choline) marks a significant breakthrough for individuals aged four and older battling hyperphagia due to Prader-Willi syndrome. With promising results from clinical trials, this new treatment offers renewed hope for families facing this challenging condition, set to be available in April 2025.

1 of 1

Story summary

The FDA's recent approval of Vykat XR (diazoxide choline) marks a significant breakthrough for individuals aged four and older battling hyperphagia due to Prader-Willi syndrome. With promising results from clinical trials, this new treatment offers renewed hope for families facing this challenging condition, set to be available in April 2025.